COEP
Coeptis Therapeutics Holdings, Inc.14.43
-0.66-4.37%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
77.06MP/E (TTM)
-Basic EPS (TTM)
-3.59Dividend Yield
0%Recent Filings
10-K
FY2025 results
Coeptis Therapeutics posted FY2025 net loss of $12.3M, up 13% y/y from $10.9M, while tech segment NexGenAI drove first meaningful revenue of $1.4M from lead generation—yet biotech R&D weighed heavy after Deverra license costs. Operating expenses jumped 41% to $14.2M on merger consulting and stock comp, though R&D eased post-SSA end. Cash swelled to $5.7M via private placements. Losses persist. Going concern doubts loom large.
8-K
Option repricing done; Nasdaq compliant
Coeptis Therapeutics implemented its approved option repricing/exchange program on February 11, 2026, letting officers and directors swap high-priced options for restricted stock or reprice them, while accelerating all vesting. Key insiders like David Mehalick exchanged options for 51,250 restricted shares and exercised others for 148,875 more. Nasdaq confirmed compliance regained on February 9 over the annual meeting issue. Insiders now hold more skin in the game.
8-K
Merger with Z Squared approved
Coeptis Therapeutics stockholders overwhelmingly approved the merger with Z Squared on January 30, 2026, with 3.47M FOR votes versus 225K against, paving the way for a change of control. They also greenlit a spin-out of biopharma ops excluding GEAR Therapeutics, name change to Z Squared Inc., new equity plan, and post-merger board. All nine proposals passed handily. Quorum hit with 65% turnout.
8-K
Nasdaq delisting warning issued
Coeptis Therapeutics received a Nasdaq delisting notice on January 12, 2026, for failing to hold its annual shareholder meeting by December 31, 2024, violating Rules 5620(a) and 5810(c)(2)G. It has 45 days to submit a compliance plan, potentially earning until June 29, 2026. Meeting set for January 30. Nasdaq status hangs in the balance.
10-Q
Q3 FY2025 results
Coeptis Therapeutics posted first sales of $237k in Q3 2025 ended September 30 from its Technology segment's NexGenAI platform (y/y from $0), yielding $192k gross profit, yet biotech R&D drove a $2.5M operating loss, worse than $2.1M last year on higher professional fees. Nine-month revenue hit $501k (y/y from $0) against $11.1M operating loss; net loss swelled to $10.7M from $7.9M, with the gap tied to $1.0M stock-based comp and $568k unrealized securities hit. Cash climbed to $4.9M on $11.3M financing inflows, debt cleared to $250k (SBA loan plus defaulted note). Shares outstanding tripled to 5.2M. Cash burn persists.
BEAM
Beam Therapeutics Inc.
26.76-0.07
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CELU
Celularity Inc.
1.35-0.05
CLLS
Cellectis S.A.
4.06-0.73
COYA
Coya Therapeutics, Inc.
5.83-0.08
CUBT
CURATIVE BIOTECHNOLOGY INC.
0.01+0.00
KPTI
Karyopharm Therapeutics Inc.
6.33-0.38
KYTX
Kyverna Therapeutics, Inc.
10.24-0.58
TCBPY
TC BioPharm (Holdings) plc
0.11+0.00
VINC
Vincerx Pharma, Inc.
0.01+0.00